An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

Concomitant use of statins improved survival among people with cancer treated with immune checkpoint inhibitors, according to ...

Niraparib in patients with BRCA-mutated unresectable or recurrent biliary tract, pancreatic and other gastrointestinal cancers: An investigator-initiated phase 2 trial (NIR-B trial). This is an ASCO ...

A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.